» Articles » PMID: 25838164

Patterns and Utility of Routine Surveillance in High Grade Endometrial Cancer

Overview
Journal Gynecol Oncol
Date 2015 Apr 4
PMID 25838164
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate surveillance methods and their utility in detecting recurrence of disease in a high grade endometrial cancer population.

Methods: We performed a multi-institutional retrospective chart review of women diagnosed with high grade endometrial cancer between the years 2000 and 2011. Surveillance data was abstracted and analyzed. Surveillance method leading to detection of recurrence was identified and compared by stage of disease and site of recurrence.

Results: Two hundred and fifty-four patients met the criteria for inclusion. Vaginal cytology was performed in the majority of early stage patients, but was utilized less in advanced stage patients. CA-125 and CT imaging were used more frequently in advanced stage patients compared to early stage. Thirty-six percent of patients experienced a recurrence and the majority of initial recurrences (76%) had a distant component. Modalities that detected cancer recurrences were: symptoms (56%), physical exam (18%), surveillance CT (15%), CA-125 (10%), and vaginal cytology (1%). All local recurrences were detected by symptoms or physical exam findings. While the majority of loco-regional and distant recurrences (68%) were detected by symptoms or physical exam, 28% were detected by surveillance CT scan or CA 125. One loco-regional recurrence was identified by vaginal cytology but no recurrences with a distant component detected by this modality.

Conclusions: Symptoms and physical examination identify the majority of high grade endometrial cancer recurrences, while vaginal cytology is the least likely surveillance modality to identify a recurrence. The role of CT and CA-125 surveillance outside of a clinical trial needs to be further reviewed.

Citing Articles

Isolated vaginal recurrence in women with stage I endometrial cancer.

Rios-Doria E, Cun H, Filippova O, Mueller J, Alektiar K, Ellenson L Gynecol Oncol. 2023; 179:9-15.

PMID: 37864854 PMC: 11215939. DOI: 10.1016/j.ygyno.2023.10.011.


Recurrent patterns after postoperative radiotherapy for early stage endometrial cancer: A competing risk analysis model.

Ren K, Wang W, Sun S, Hou X, Hu K, Zhang F Cancer Med. 2021; 11(1):257-267.

PMID: 34779587 PMC: 8704144. DOI: 10.1002/cam4.4423.


Efficacy of Endometrial Cancer Follow-up Protocols: Time to Change?.

Lubrano A, Benito V, Pinar B, Molano F, Leon L Rev Bras Ginecol Obstet. 2021; 43(1):41-45.

PMID: 33513635 PMC: 10183951. DOI: 10.1055/s-0040-1721352.


Flow cytometric evaluation of crude synaptosome preparation as a way to study synaptic alteration in neurodegenerative diseases.

Postupna N, Latimer C, Keene C, Montine K, Montine T, Darvas M Neuromethods. 2020; 141:297-310.

PMID: 32139977 PMC: 7058378. DOI: 10.1007/978-1-4939-8739-9_17.


Cancer antigen 125 is associated with disease status in uterine carcinosarcoma.

Ross M, Chandler C, Matsuo K, Austin Vargo J, Elishaev E, Siripong N Rare Tumors. 2019; 11:2036361319884159.

PMID: 31741727 PMC: 6843728. DOI: 10.1177/2036361319884159.


References
1.
Connor J, Andrews J, Anderson B, Buller R . Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000; 95(5):692-6. DOI: 10.1016/s0029-7844(99)00626-2. View

2.
Zakhour M, Li A, Walsh C, Cass I, Karlan B, Rimel B . Post treatment surveillance of type II endometrial cancer patients. Gynecol Oncol. 2013; 131(3):609-12. DOI: 10.1016/j.ygyno.2013.09.008. View

3.
Morice P, Levy-Piedbois C, Ajaj S, Pautier P, Haie-Meder C, Lhomme C . Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer. Eur J Cancer. 2001; 37(8):985-90. DOI: 10.1016/s0959-8049(01)00066-1. View

4.
Keys H, Roberts J, Brunetto V, Zaino R, Spirtos N, Bloss J . A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92(3):744-51. DOI: 10.1016/j.ygyno.2003.11.048. View

5.
Tjalma W, van Dam P, Makar A, Cruickshank D . The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer. 2004; 14(5):931-7. DOI: 10.1111/j.1048-891X.2004.014532.x. View